Respiratory syncytial virus infection in children with bronchopulmonary dysplasia
- PMID: 3399292
Respiratory syncytial virus infection in children with bronchopulmonary dysplasia
Abstract
Little is known about the risk of severe illness from respiratory syncytial virus infection in children with bronchopulmonary dysplasia. A prospective study was done of the natural history of respiratory syncytial virus infection in 30 children less than 2 years of age with bronchopulmonary dysplasia who were in a home oxygen program. Surveillance to identify children with acute respiratory symptoms was done by weekly telephone interview. Symptomatic children were examined, oxygen saturation was determined by oximetry, and nasopharyngeal lavage fluid was collected for virus cultures and rapid respiratory syncytial virus antigen tests. During the 4-month study period (December to April), 27 children had one or more acute respiratory illnesses, and respiratory syncytial virus developed in 16/27 (59%). Passive smoking and greater than or equal to four members in the home increased the risk of symptomatic respiratory syncytial virus (P less than .01 and P less than .03, respectively). Of 16 children, 11 (69%) required hospitalization. Of the 11 hospitalized children with respiratory syncytial virus, nine were either still receiving oxygen at home or required oxygen therapy within the previous 3 months v none of five nonhospitalized children (P less than .005). Five of the hospitalized children were greater than 12 months of age and five had respiratory syncytial virus infection previously that had been confirmed by culture results. Hospitalizations were prolonged and complicated. Seven of 11 children were hospitalized for greater than 1 week; four were admitted to the intensive care unit; four were treated with ribavirin aerosol, and two needed mechanical ventilation. There were no deaths.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Pediatrics. 1998. PMID: 9738173 Clinical Trial.
-
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.N Engl J Med. 1993 Nov 18;329(21):1524-30. doi: 10.1056/NEJM199311183292102. N Engl J Med. 1993. PMID: 8413475 Clinical Trial.
-
Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy.Pediatrics. 2005 Jan;115(1):e7-14. doi: 10.1542/peds.2004-0059. Pediatrics. 2005. PMID: 15629968
-
Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants.Infect Dis Clin North Am. 1987 Jun;1(2):425-39. Infect Dis Clin North Am. 1987. PMID: 3332796 Review.
-
[Respiratory syncytial virus infections and preventive options].Ned Tijdschr Geneeskd. 2000 Jan 1;144(1):15-9. Ned Tijdschr Geneeskd. 2000. PMID: 10665299 Review. Dutch.
Cited by
-
The effect of passive smoking on the development of respiratory syncytial virus bronchiolitis.Eur J Epidemiol. 2000 May;16(5):465-8. doi: 10.1023/a:1007658411953. Eur J Epidemiol. 2000. PMID: 10997834
-
Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort.Arch Dis Child. 2000 Oct;83(4):313-6. doi: 10.1136/adc.83.4.313. Arch Dis Child. 2000. PMID: 10999865 Free PMC article. Clinical Trial.
-
Predictors of prolonged length of hospital stay for infants with bronchiolitis.J Investig Med. 2018 Aug;66(6):986-991. doi: 10.1136/jim-2018-000708. Epub 2018 Mar 26. J Investig Med. 2018. PMID: 29588331 Free PMC article.
-
Cell-Free Amniotic Fluid and Regenerative Medicine: Current Applications and Future Opportunities.Biomedicines. 2022 Nov 17;10(11):2960. doi: 10.3390/biomedicines10112960. Biomedicines. 2022. PMID: 36428527 Free PMC article. Review.
-
Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group.Antimicrob Agents Chemother. 1991 Jul;35(7):1469-73. doi: 10.1128/AAC.35.7.1469. Antimicrob Agents Chemother. 1991. PMID: 1718213 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous